Zymeworks BC Inc (NASDAQ: ZYME) on Monday, plunged -3.72% from the previous trading day, before settling in for the closing price of $12.37. Within the past 52 weeks, ZYME’s price has moved between $7.97 and $17.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 273.04%. The company achieved an average annual earnings per share of -3.28%. With a float of $67.30 million, this company’s outstanding shares have now reached $68.96 million.
The extent of productivity of a business whose workforce counts for 286 workers is very important to gauge. In terms of profitability, gross margin is 50.29%, operating margin of -157.03%, and the pretax margin is -152.82%.
Zymeworks BC Inc (ZYME) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zymeworks BC Inc is 4.07%, while institutional ownership is 97.46%. The most recent insider transaction that took place on Mar 25 ’25, was worth 690,452. In this transaction Director of this company bought 53,501 shares at a rate of $12.91, taking the stock ownership to the 17,211,303 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 43,848 for $12.24, making the entire transaction worth $536,857. This insider now owns 17,255,151 shares in total.
Zymeworks BC Inc (ZYME) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.14% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
Zymeworks BC Inc (ZYME) is currently performing well based on its current performance indicators. A quick ratio of 3.40 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Zymeworks BC Inc (ZYME)
The latest stats from [Zymeworks BC Inc, ZYME] show that its last 5-days average volume of 0.5 million was inferior to 0.53 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 30.83%. Additionally, its Average True Range was 0.67.
During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 14.09%, which indicates a significant decrease from 22.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.76% in the past 14 days, which was lower than the 57.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.53, while its 200-day Moving Average is $12.57. Now, the first resistance to watch is $12.16. This is followed by the second major resistance level at $12.42. The third major resistance level sits at $12.74. If the price goes on to break the first support level at $11.59, it is likely to go to the next support level at $11.27. The third support level lies at $11.01 if the price breaches the second support level.
Zymeworks BC Inc (NASDAQ: ZYME) Key Stats
Market capitalization of the company is 835.45 million based on 69,577K outstanding shares. Right now, sales total 76,300 K and income totals -122,700 K. The company made 31,030 K in profit during its latest quarter, and -23,510 K in sales during its previous quarter.
